Administration’s 2013 Budget Could Discourage Development of Cures and Breakthrough Medicines, Limit Patient Choice And Fo – FierceBiotech
WASHINGTON--(BUSINESS WIRE)-- Biotechnology Industry Organization (BIO ... during the consideration of the biosimilar pathway and is now settled U.S. law. The 12-year period continues to maintain strong bipartisan support in the Congress.
Subscribe to LegalLaw247.Com Newsletter
